• Received 4 purchase orders, 33.3% growth over prior period
• Completed A$6.5m placement, secured A$18m vendor financing facility
• Progressing FDA clearance for bone mineral density software module

CurveBeam AI Limited (ASX: CVB) reported its Appendix 4C and quarterly activity report for the period ended 30 September 2025 (Q1 FY26). The company received purchase orders for 4 devices in Q1 FY26, a 33.3% growth over the prior corresponding period. This included 3 HiRise devices and 1 InReach device, all sold in the USA. Receipts from customers for the quarter were A$1.374m, down from A$2.410m in Q1 FY25, reflecting the northern hemisphere summer quarter. CurveBeam AI completed a A$6.5m placement from institutional and sophisticated investors during the quarter. The company also signed an agreement with a Swiss financing partner for a A$18m (€10m) vendor financing facility. This will improve the ability of capital-constrained practices to acquire the HiRise device. Progress continued on the bone mineral density (BMD) module under the FDA's 510(k) Class II regulatory pathway, with the company targeting late H1 CY26 for FDA clearance. CurveBeam AI also entered into a 10-year exclusive distribution agreement for China, Hong Kong, Macau and Taiwan, with an upfront investment of A$4m and a further A$6m subject to milestones.

The company maintains a target of mid-CY26 for FDA clearance of the bone mineral density (BMD) Multiple Detector CT (MDCT) software module.

CurveBeam AI is focused on progressing the FDA clearance for its BMD software module, expanding its distribution in China through the new joint venture, and leveraging the new vendor financing facility to drive further sales growth.